APA (7th ed.) Citation

Y, G., ZJ, X., JD, Z., XM, W., Y, J., Q, Y., . . . J, Q. (2022). SLC22A3 methylation-mediated gene silencing predicts adverse prognosis in acute myeloid leukemia. Clinical epigenetics, 14(1), 162. https://doi.org/10.1186/s13148-022-01373-w

Chicago Style (17th ed.) Citation

Y, Gu, et al. "SLC22A3 Methylation-mediated Gene Silencing Predicts Adverse Prognosis in Acute Myeloid Leukemia." Clinical Epigenetics 14, no. 1 (2022): 162. https://doi.org/10.1186/s13148-022-01373-w.

MLA (9th ed.) Citation

Y, Gu, et al. "SLC22A3 Methylation-mediated Gene Silencing Predicts Adverse Prognosis in Acute Myeloid Leukemia." Clinical Epigenetics, vol. 14, no. 1, 2022, p. 162, https://doi.org/10.1186/s13148-022-01373-w.